{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T15:53:29Z","timestamp":1790610809729,"version":"4.1.0"},"reference-count":22,"publisher":"Wiley","issue":"S2","license":[{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100010638","name":"Huntsman Cancer Institute, University of Utah","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010638","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Obesity"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aimed to assess the spectrum and frequency of adverse events (AEs) linked to glucagon\u2010like peptide\u20101 receptor agonists (GLP\u20101RAs) using the US FDA Adverse Event Reporting System (FAERS). Emphasis was placed on emerging safety concerns in context\u2010specific use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective analysis of FAERS reports between 2012 and 2025 was conducted. Five commonly prescribed FDA\u2010approved GLP\u20101RAs were included. Disproportionality analyses were applied to detect AE signals. Subgroup analyses evaluated associations by indication, GLP\u20101RAs compared to other drugs, and AEs specific to individual GLP\u20101RAs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      From over 18 million FAERS reports, 137,451 involved GLP\u20101RAs. The most frequent AEs were gastrointestinal, nutritional and metabolic, and psychiatric disorders, occurring at higher rates compared to other drugs. In diabetes use, GLP\u20101RAs were associated with retinopathy, hearing loss, and cataracts. In contrast, when prescribed for weight management\/obesity, nutritional, metabolic, and psychiatric AEs predominated. We also developed an open\u2010access portal for AE exploration, available at\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/glp1.tanlab.org\">http:\/\/glp1.tanlab.org<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      GLP\u20101RAs are linked to a broad range of AEs across indications. These findings stress the need for careful clinical monitoring and long\u2010term safety evaluation. This study also illustrates how real\u2010world evidence can inform safety communications, as well as hypothesis generation for research on next\u2010generation GLP\u20101RAs.\n                      <jats:boxed-text content-type=\"graphic\" position=\"anchor\">\n                        <jats:graphic xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" mimetype=\"image\/png\" position=\"anchor\" specific-use=\"enlarged-web-image\" xlink:href=\"graphic\/oby70176-gra-0001-m.png\">\n                          <jats:alt-text>image<\/jats:alt-text>\n                        <\/jats:graphic>\n                      <\/jats:boxed-text>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/oby.70176","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T07:32:18Z","timestamp":1773041538000},"page":"101-108","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Evaluating the Evolving Real\u2010World Adverse Events of\n                    <scp>GLP<\/scp>\n                    \u2010\n                    <scp>1RAs<\/scp>\n                    Using\n                    <scp>FDA<\/scp>\n                    Adverse Event Reporting System (\n                    <scp>FAERS<\/scp>\n                    )"],"prefix":"10.1002","volume":"34","author":[{"given":"David","family":"Stone","sequence":"first","affiliation":[{"name":"Departments of Oncological Sciences and Biomedical Informatics University of Utah  Salt Lake City Utah USA"},{"name":"Huntsman Cancer Institute University of Utah  Salt Lake City Utah USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Playdon","sequence":"additional","affiliation":[{"name":"Huntsman Cancer Institute University of Utah  Salt Lake City Utah USA"},{"name":"Department of Nutrition and Integrative Physiology University of Utah  Salt Lake City Utah USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen D.","family":"Hursting","sequence":"additional","affiliation":[{"name":"Department of Nutrition University of North Carolina at Chapel Hill  Chapel Hill North Carolina USA"},{"name":"Nutrition Research Institute University of Carolina at Chapel Hill  Kannapolis North Carolina USA"},{"name":"Lineberger Comprehensive Cancer Center University of North Carolina at Chapel Hill  Chapel Hill North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aik Choon","family":"Tan","sequence":"additional","affiliation":[{"name":"Departments of Oncological Sciences and Biomedical Informatics University of Utah  Salt Lake City Utah USA"},{"name":"Huntsman Cancer Institute University of Utah  Salt Lake City Utah USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,3,9]]},"reference":[{"key":"e_1_2_10_2_1","unstructured":"World Health Organization \u201cObesity and Overweight \u201daccessed August 31 2025 https:\/\/www.who.int\/news\u2010room\/fact\u2010sheets\/detail\/obesity\u2010and\u2010overweight."},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106320"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-019-00826-0"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206038"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-01206-9"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics14242829"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103385"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.numecd.2024.09.028"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-068127"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-23726-4"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2011.04037.x"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.668"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.2174\/0113816128375766250720234005"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109374"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.r1512"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2025.0679"},{"key":"e_1_2_10_18_1","article-title":"Association of Glucagon\u2010Like Peptide\u20101 Receptor Agonists With Cancer Risk in Older Adults With Type 2 Diabetes","volume":"34","author":"Lu Y.","year":"2026","journal-title":"Obesity (Silver Spring)"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djae260"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.21305"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.26327"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2025.2588634"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2025.2681"}],"container-title":["Obesity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/oby.70176","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/oby.70176","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/oby.70176","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T08:25:31Z","timestamp":1788337531000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/oby.70176"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,9]]},"references-count":22,"journal-issue":{"issue":"S2","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1002\/oby.70176"],"URL":"https:\/\/doi.org\/10.1002\/oby.70176","archive":["Portico"],"relation":{},"ISSN":["1930-7381","1930-739X"],"issn-type":[{"value":"1930-7381","type":"print"},{"value":"1930-739X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,9]]},"assertion":[{"value":"2025-09-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}